Araştırma
Eğitim
Çözümler
Oturum Aç
TR
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Vincenza Conteduca has not added Biography.
If you are Vincenza Conteduca and would like to personalize this page please email our Author Liaison for assistance.
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone.
Oncotarget Dec, 2014 | Pubmed ID: 25504434
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.
Oncotarget Jun, 2016 | Pubmed ID: 27191887
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
Oncotarget 08, 2016 | Pubmed ID: 27409344
Cell-free DNA as a diagnostic marker for cancer: current insights.
OncoTargets and therapy , 2016 | Pubmed ID: 27822059
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Scientific reports Nov, 2017 | Pubmed ID: 29138500
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
Samanta Salvi1,
Vincenza Conteduca1,
Filippo Martignano1,
Giorgia Gurioli1,
Daniele Calistri1,
Valentina Casadio1
1, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
Gizlilik
Kullanım Şartları
İlkeler
Bize Ulaşın
KÜTÜPHANEYE TAVSİYE ET
JoVE HABER BÜLTENLERİ
JoVE Journal
Yöntem Koleksiyonları
JoVE Encyclopedia of Experiments
Arşiv
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Fakülte Kaynak Merkezi
Yazarlar
Kütüphaneciler
Erişim
JoVE Hakkında
Telif Hakkı © 2020 MyJove Corporation. Tüm hakları saklıdır
